Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;13(5):534-545.
doi: 10.1007/s12072-019-09970-3. Epub 2019 Jul 30.

Reversal of NASH fibrosis with pharmacotherapy

Joseph J Alukal  1 , Paul J Thuluvath  2   3
Affiliations
Review

Reversal of NASH fibrosis with pharmacotherapy

Joseph J Alukal et al. Hepatol Int. 2019 Sep.

Abstract

NAFLD is a spectrum of liver disease starting with fatty liver at one end of the spectrum and cirrhosis or liver cancer at the other end. Worldwide, NAFLD has become one of the most common liver diseases and it has also become one of the leading indications for liver transplantation. Our understanding of the NAFLD epidemiology, pathogenesis and its progression to cirrhosis has improved over the last 2 decades. Currently, however, there are no FDA-approved treatment options for fibrosis resulting from NAFLD. A number of compounds targeting multiple pathways involved in the progression of NAFLD are currently in phase 2-3 trials. In this review, we will briefly discuss the epidemiology, the pathogenesis and the current status of treatment of NAFLD.

Keywords: Antifibrotic agents; NAFLD; NASH.

PubMed Disclaimer

References

    1. Physiol Rev. 2008 Jan;88(1):125-72 - PubMed
    1. Nat Biotechnol. 2008 Apr;26(4):431-42 - PubMed
    1. Hepatology. 2008 Nov;48(5):1632-43 - PubMed
    1. J Hepatol. 2009 Aug;51(2):371-9 - PubMed
    1. Am J Physiol Gastrointest Liver Physiol. 2009 Dec;297(6):G1093-106 - PubMed

MeSH terms

LinkOut - more resources